

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

3 of 8

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer et al.
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020 J.DOC

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	†
		Office ²	Number	Kind Code ³ (if known)				
EC	CA	WO	01/92282	A2&3	Novirio (Idenix); Univ. ... Cagliari	06-12-2001		
	CB	WO	01/96353	A2	Novirio Pharm. (Idenix); C.N.R.S.	21-20-2001	12/01	
	CC	WO	02/057287	A2	Merck; Isis Pharmaceuticals	07-25-2002		
	CD	WO	02/057425	A2	Merck; Isis Pharmaceuticals	07-25-2002		
	CE	WO	02/18404	A2	Hoffman-La Roche AG	03-07-2002		
	CF	WO	02/32414	A2	Schering Corporation	04-25-2002		
	CG	WO	02/32920	A2	Pharmasset	04-25-2002		
	CH	WO	02/48165	A2	Pharmasset	06-20-2002		
	CI	WO	03/024461	A1	Schering Corporation	03-27-2003		
	CJ	WO	04/003138	A2	Merck & Co., Isis Pharmaceutical	01-08-2004		
CK	CK	WO	04/009020	A2	Merck & Co., Isis Pharmaceutical	01-29-2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	†
EC	CL	BAGINSKI, S. G. et al., "Mechanism of action of a pestivirus antiviral compound," <i>PNAS USA</i> , 97(14): 7981-7986 (2000).	
	CM	BATTAGLIA, A.M. et al., "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection", <i>Ann. Pharmacother.</i> , 34:487-494 (2000).	
	CN	BEIGELMAN, L.N., et al., "Functionally complete analogues of nucleosides. The use of D-glucose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides," <i>Bioorg. Khim.</i> , 12(10):1359-1365 (1986). <i>Abstract in English at p. 1365.</i> <i>Considered English Abstract</i>	Abstract in English at p. 1365
	CO	BEIGELMAN, L.N., et al., "New synthesis of 2'-C-methylnucleosides starting from D-glucose and D-ribose," <i>Carbohydrate Research</i> , 166:219-232 (1987).	
	CP	BENZARIA, S., et al., "Synthesis of potential prodrugs of β -L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50:A79 (2001).	
	CQ	BERENGUER, M. et al., "Hepatitis C virus in the transplant setting", <i>Antivir. Ther.</i> , 3 (Suppl 3):125-136 (1998).	
	CR	BERMAN, E. et al., "Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells," <i>Blood</i> , 74(4):1281-1286 (1989)	
CK	CS	BHAT et al. (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.); p A75).	

Examiner
Signature

G. K. Kishan

Date
Considered

12/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-027-999	10/735,408
APPLICANT	CONFIRMATION NO.
Storer, et al.	2099
FILING DATE	ART UNIT
December 12, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
<i>cdl</i>	A01	3,074,929	1/22/63	Hitchings, et al.	
	A02	3,116,282	12/31/63	Hunter	
	A03	3,891,623	6/24/75	Vorbruggen, et al.	
	A04	3,480,613	11/25/69	Walton	
	A05	4,209,613	6/24/80	Vorbruggen	
	A06	4,605,659	8/12/86	Verheyden, et al.	
	A07	4,689,404	8/25/87	Kawada, et al.	
	A08	4,754,026	6/28/88	Kawada, et al.	
	A09	4,814,477	3/21/89	Wijnberg, et al.	
	A10	4,880,784	11/14/89	Robins, et al.	
	A11	5,034,394	7/23/91	Daluge	
	A12	5,122,517	6/16/92	Vince, et al.	
	A13	5,156,797	10/26/93	Chou, et al. 5,256,797	
	A14	5,200,514	4/06/93	Chu	
	A15	5,371,210	12/06/94	Chou, et al.	
	A16	5,372,808	12/13/94	Blatt, et al.	
	A17	5,401,861	3/28/95	Chou, et al.	
	A18	5,539,116	7/23/96	Liotta, et al.	
	A19	5,565,438	10/15/96	Chu, et al.	
	A20	5,567,688	10/22/96	Chu, et al.	
	A21	5,587,362	12/24/96	Chu, et al.	
	A22	5,606,048	2/25/97	Chou, et al.	
	A23	5,676,942	10/14/97	Testa, et al.	
	A24	5,696,277	12/09/97	Hosteller, et al.	
	A25	5,738,845	4/14/98	Imakawa	
	A26	5,744,600	4/28/98	Mansuri, et al.	
	A27	5,750,676	5/12/98	Vorbruggen, et al.	
	A28	5,763,418	6/09/98	Matsuda, et al.	
	A29	5,780,617	7/14/98	Van den Bosch, et al.	
<i>ck</i>	A30	5,789,608	8/04/98	Glazier	

LAI-2912074v1

EXAMINER

G. Krishnam

DATE CONSIDERED

12/28/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RAP
8/13/09

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
CEK	B19	GB 1,163,103	9/4/69	Merck & Co. Inc.		
	B20	GB 1,187,824	5/02/66	Walton		
	B21	GB 1,209,654	10/21/70	Walton		
	B22	GB 1,542,442	3/21/79	Schering AG		
	B23	JP 48048495	9/21/71	Kojin Co., Ltd.	English Abstract Provided	
	B24	JP 71021872	3/68	Sankyo Co., Ltd.	English Abstract Provided	
	B25	JP 09059292	3/04/97	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B26	JP 2091022	3/30/90	Univ. of Minnesota	English Abstract Provided	
	B27	JP 06135988	5/17/94	Toagosei Chemical Ind., Ltd.	English Abstract Provided	
	B28	JP 06211890	8/02/94	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B29	JP 06228186	8/16/94	Yamasa Shoyu Co., Ltd.	English Abstract Provided	
	B30	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho	English Abstract Provided	
	B31	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.	English Abstract Provided	
	B32	JP 61263996	11/21/86	Hong	English Abstract Provided	
	B33	JP 63215694	9/8/88	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B34	WO 92/15308	9/17/92	Painter, et al.		
	B35	WO 92/18517	10/29/92	Cheng, et al.		
	B36	WO 94/001117	1/20/94	Koszalka, et al.		
	B37	WO 98/016184	4/23/98	ICN Pharmaceuticals		
	B38	WO 99/023104	5/14/99	Klecker, et al.		
	B39	WO 99/052514	10/21/99	Eli Lilly and Co.		
	B40	WO 00/009531	2/24/00	Novirio Pharmaceuticals, Ltd.		
	B41	WO 01/049700	07/12/01	Biochem Pharma Inc., Can.		
	B42	WO 01/068663	9/20/01	Ribapharm Corp.		
	B43	WO 01/091737	12/06/01	Sommadossi, et al.		
	B44	WO 02/003997	1/17/02	Ribapharm, Inc.		
	B45	WO 02/070533	9/12/02	Pharmasset Ltd.		
	B46	WO 02/094289	11/28/02	F. Hoffmann-La Roche AG		
	B47	WO 02/100415	12/19/02	F. Hoffmann-La Roche AG		
CEK	B48	WO 03/026589	4/3/03	Idenix Pharma.; CNRS; U. Montp.		

LAI-2912074v1

EXAMINER <i>G. Karislan</i>	DATE CONSIDERED <i>12/28/07</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	